Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma

References

• Liu J, Song B, Fan T, et al. Pathological and clinical characteristics of 1,248 non-Hodgkin’s lymphomas from a regional cancer hospital in Shandong, China. Asian Pac J Cancer Prev. 2011;12(11):3055–3061.
   PubMedGoogle Scholar
• Chakrabarti S, Sarkar S, Goswami BK, et al. Hodgkin’s and non-Hodgkin’s lymphomas in an indian rural medical institution: comparative clinicopathologic analysis. Asian Pac J Cancer Prev. 2010;11(6):1605–1608.
   PubMedGoogle Scholar
• Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 2004;100(2):366–375. doi: 10.1002/cncr.11908
   PubMed Web of Science ®Google Scholar
• Tse E, Kwong Y-L. How I treat NK/T-cell lymphomas. Blood. 2013;121(25):4997–5005. doi: 10.1182/blood-2013-01-453233
   PubMed Web of Science ®Google Scholar
• Au WY, Ma SY, Chim CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol. 2005;16(2):206–214. doi: 10.1093/annonc/mdi037
   PubMed Web of Science ®Google Scholar
• Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000;18(1):54–63.
   PubMed Web of Science ®Google Scholar
• Cheung MM, Chan JK, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998;16(1):70–77.
   PubMed Web of Science ®Google Scholar
• Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006;24(1):181–189. doi: 10.1200/JCO.2005.03.2573
   PubMed Web of Science ®Google Scholar
• Aviles A, Neri N, Fernandez R, et al. Combined therapy in untreated patients improves outcome in nasal NK/T lymphoma: results of a clinical trial. Med Oncol. 2013;30(3):637. doi:10.1007/s12032-013-0637-1
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol. 2009;27(35):6027–6032. doi: 10.1200/JCO.2009.23.8592
   PubMed Web of Science ®Google Scholar
• Kim WS, Song SY, Ahn YC, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol. 2001;12(3):349–352. doi: 10.1023/A:1011144911781
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009;27(33):5594–5600. doi: 10.1200/JCO.2009.23.8295
   PubMed Web of Science ®Google Scholar
• Jiang M, Zhang H, Jiang Y, et al. Phase 2 trial of ‘sandwich’ L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer. 2012;118(13):3294–3301. doi: 10.1002/cncr.26629
   PubMed Web of Science ®Google Scholar
• Wang L, Wang ZH, Chen XQ, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013;119(2):348–355. doi: 10.1002/cncr.27752
   PubMed Web of Science ®Google Scholar
• Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120(15):2973–2980. doi: 10.1182/blood-2012-05-431460
   PubMed Web of Science ®Google Scholar
• Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000;18(7):1525–1532.
   PubMed Web of Science ®Google Scholar
• Alfieri DR. Pegaspargase. Pediatr Nurs. 1995;21(5):471–490.
   PubMedGoogle Scholar
• Wu X, Li P, Zhao J, et al. A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type. Clin Oncol (R Coll Radiol). 2008;20(8):619–625. doi: 10.1016/j.clon.2008.05.011
   PubMed Web of Science ®Google Scholar
• Guo Y, Lu JJ, Ma X, et al. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy. Oral Oncol. 2008;44(1):23–30. doi: 10.1016/j.oraloncology.2006.11.020
   PubMed Web of Science ®Google Scholar
• Wang B, Li XQ, Ma X, et al. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol. 2008;83(10):795–799. doi: 10.1002/ajh.21256
   PubMed Web of Science ®Google Scholar
• Kim M, Kim TM, Kim KH, et al. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL). Ann Hematol. 2015;94(3):437–444. doi: 10.1007/s00277-014-2228-4
   PubMed Web of Science ®Google Scholar
• Nomura E, Isoda K, Yamanaka K, et al. Extra nodal NK/T-cell lymphoma nasal type that responded to DeVIC combination chemotherapy. J Dermatol. 2005;32(3):204–209. doi: 10.1111/j.1346-8138.2005.tb00746.x
   PubMed Web of Science ®Google Scholar
• Zhou Z, Li X, Chen C, et al. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients. Ann Hematol. 2014;93(11):1889–1894. doi: 10.1007/s00277-014-2136-7
   PubMed Web of Science ®Google Scholar
• Ando M, Sugimoto K, Kitoh T, et al. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol. 2005;130(6):860–868. doi: 10.1111/j.1365-2141.2005.05694.x
   PubMed Web of Science ®Google Scholar
• Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117(6):1834–1839. doi: 10.1182/blood-2010-09-307454
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29(33):4410–4416. doi: 10.1200/JCO.2011.35.6287
   PubMed Web of Science ®Google Scholar
• Wang L, Wang WD, Xia ZJ, et al. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up. Med Oncol. 2014;31(3):860. doi:10.1007/s12032-014-0860-4
   PubMed Web of Science ®Google Scholar
• Dinndorf PA, Gootenberg J, Cohen MH, et al. FDA drug approval summary: pegaspargase (oncaspar(R)) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007;12(8):991–998. doi: 10.1634/theoncologist.12-8-991
   PubMed Web of Science ®Google Scholar
• Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109(7):2744–2750.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol. 2010;21(4):860–863. doi: 10.1093/annonc/mdp508
   PubMed Web of Science ®Google Scholar
• Evens AM, Rosen ST, Helenowski I, et al. A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. Br J Haematol. 2013;163(1):55–61. doi: 10.1111/bjh.12488
   PubMed Web of Science ®Google Scholar
• Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica. 2013;98(11):1726–1731. doi: 10.3324/haematol.2013.090597
   PubMed Web of Science ®Google Scholar
• El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007;18(8):1363–1368. doi: 10.1093/annonc/mdm133
   PubMed Web of Science ®Google Scholar
• Tham IW, Lee KM, Yap SP, et al. Outcome of patients with nasal natural killer (NK)/T-cell lymphoma treated with radiotherapy, with or without chemotherapy. Head Neck. 2006;28(2):126–134. doi: 10.1002/hed.20314
   PubMed Web of Science ®Google Scholar
• Huang MJ, Jiang Y, Liu WP, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys. 2008;70(1):166–174. doi: 10.1016/j.ijrobp.2007.05.073
   PubMed Web of Science ®Google Scholar
• Koom WS, Chung EJ, Yang WI, et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 2004;59(4):1127–1137. doi: 10.1016/j.ijrobp.2003.12.006
   PubMed Web of Science ®Google Scholar
• Wang L, Bi XW, Xia ZJ, et al. Radiation dose reduction for patients with extranodal NK/T-cell lymphoma with complete response after initial induction chemotherapy. OncoTargets Ther. 2016;9:5875–5881. doi: 10.2147/OTT.S116591
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24(4):612–618. doi: 10.1200/JCO.2005.04.1384
   PubMed Web of Science ®Google Scholar
• Kim TM, Park YH, Lee S-Y, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type. Blood. 2005;106(12):3785–3790. doi: 10.1182/blood-2005-05-2056
   PubMed Web of Science ®Google Scholar
• Kim HJ, Bang SM, Lee J, et al. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant. 2006;37(9):819–824. doi: 10.1038/sj.bmt.1705349
   PubMed Web of Science ®Google Scholar
• Kim SJ, Choi JY, Hyun SH, et al. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. Lancet Haematol. 2015;2(2):e66–e74. doi: 10.1016/S2352-3026(15)00002-2
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(3):389–400. doi: 10.1016/S1470-2045(15)00533-1
   PubMed Web of Science ®Google Scholar
• Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011;118(23):6018–6022. doi: 10.1182/blood-2011-05-354142
   PubMed Web of Science ®Google Scholar